14 February 2023 - - US-based clinical-stage life sciences company Revelation Biosciences Inc. (NASDAQ: REVB) has closed public offering of 2,888,600 shares of its common stock and 336,400 pre-funded warrants to purchase shares of common stock, together with warrants to purchase up to 6.45m shares of its common stock at an offering price to the public of USD 4.83 per share and associated warrant, or USD 4.8299 per pre-funded warrant and associated warrant, the company said.

The warrants have an exercise price of USD 5.36 per share, are exercisable upon issuance, and will expire five years following the date of issuance.

Roth Capital Partners acted as sole placement agent for the offering.

The gross proceeds to the company from the offering are approximately USD 15.6 m, before deducting the placement agent's fees and other offering expenses payable by Revelation.

The company intends to use the net proceeds from this offering to further the development of REVTx-100 and REVTx-300 including the manufacturing of clinical supply of our drug product, to conduct, a combined Phase 1a clinical study for REVTx-100 and REVTx-300, to conduct, a Phase 1b clinical study for REVTx-100 for the prevention of surgical site infection in colorectal surgery, to conduct, a Phase 1b clinical study for REVTx-300 for the prevention and treatment of AKI due to cardiac surgery, (v) necessary preclinical work for REVTx-100 and REVTx-300, continue to develop other products and therapies, and (v) fund working capital and general corporate purposes using any remaining amounts.

The securities described above were offered pursuant to a registration statement on form S-1 (File No. 333-268576), as amended, that was declared effective by the US Securities and Exchange Commission, on February 9, 2023, and an additional registration statement filed with the SEC on February 9, 2023 pursuant to Rule 462(b) under the Securities Act of 1933, as amended.

Revelation Biosciences, Inc. is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.